Send me real-time posts from this site at my email

Here's Why Autolus Therapeutics Is Surging Today

What happened

Shares of Autolus Therapeutics (NASDAQ: AUTL), a clinical-stage biopharmaceutical company, are on the move after the company announced a new deal with Moderna (NASDAQ: MRNA). Investors excited about Autolus Therapeutics' potential role in Moderna's commercialization of RNA-based therapeutics drove the stock more than 25% higher when the market opened, but the gains have subsided as investors pick apart the details. Autolus Therapeutics' stock price was 13% higher as of 11:18 a.m. EDT on Monday.

So what

Autolus is developing a whole new class of reprogrammed T-cell therapies to treat cancer and not RNA-based drugs like Moderna. Under the terms of a new exclusive access agreement, though, Moderna could incorporate some of Autolus' proprietary binders into new cancer therapy candidates.

Image source: Getty Images.

It appears Moderna wants to combine its RNA technology with Autolus' proprietary binders to train harvested T-cells to recognize and bind to targets found on cancer cells. All of Moderna's drug candidates rely on RNA, but RNA can spur dangerous inflammatory reactions that will keep its usage in new drugs limited to products that don't require repeat dosing.

Now what

Granting larger drugmakers exclusive rights to license a new drug target is a big deal if your new partner is willing to pay a significant sum upfront for those rights. Autolus Therapeutics is eligible to receive payments each time Moderna actually licenses a new target, which hasn't happened yet. In other words, Autolus gave up its ability to retain ownership of up to four new cancer drug targets for the ability to tell investors it's partnered up with a big-name biotech company.

Autolus Therapeutics' lead candidate, AUTO1, is a CD19-directed CAR-T therapy that could be better than similar therapies that have been available since 2017. Instead of trying to follow it higher, it's probably best to tread lightly around this risky biotech stock for the foreseeable future.

10 stocks we like better than Autolus Therapeutics Plc
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Autolus Therapeutics Plc wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue